SFERA Archivio dei prodotti della Ricerca dell'Università di Ferrara

CAMARDA, Valeria
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 5.006
AS - Asia 1.896
EU - Europa 1.043
SA - Sud America 218
AF - Africa 37
OC - Oceania 3
Continente sconosciuto - Info sul continente non disponibili 2
Totale 8.205
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 4.931
SG - Singapore 677
CN - Cina 519
VN - Vietnam 219
DE - Germania 212
UA - Ucraina 170
BR - Brasile 168
GB - Regno Unito 163
IT - Italia 146
TR - Turchia 130
HK - Hong Kong 120
FI - Finlandia 97
FR - Francia 62
SE - Svezia 55
IN - India 44
CA - Canada 43
JP - Giappone 43
BD - Bangladesh 39
RU - Federazione Russa 39
MX - Messico 25
PK - Pakistan 22
NL - Olanda 20
PL - Polonia 19
AR - Argentina 18
IQ - Iraq 16
ZA - Sudafrica 15
BE - Belgio 12
ID - Indonesia 12
CO - Colombia 10
ES - Italia 10
LT - Lituania 9
UZ - Uzbekistan 9
TN - Tunisia 7
AE - Emirati Arabi Uniti 6
AT - Austria 6
EC - Ecuador 6
MA - Marocco 6
SA - Arabia Saudita 6
CL - Cile 5
MY - Malesia 5
PH - Filippine 5
IE - Irlanda 4
AU - Australia 3
BG - Bulgaria 3
CH - Svizzera 3
EG - Egitto 3
IL - Israele 3
JM - Giamaica 3
PY - Paraguay 3
TH - Thailandia 3
UY - Uruguay 3
VE - Venezuela 3
A2 - ???statistics.table.value.countryCode.A2??? 2
AL - Albania 2
BH - Bahrain 2
CZ - Repubblica Ceca 2
DZ - Algeria 2
ET - Etiopia 2
IR - Iran 2
KR - Corea 2
KZ - Kazakistan 2
RO - Romania 2
AM - Armenia 1
AZ - Azerbaigian 1
BA - Bosnia-Erzegovina 1
BO - Bolivia 1
CY - Cipro 1
DO - Repubblica Dominicana 1
GE - Georgia 1
HU - Ungheria 1
JO - Giordania 1
KE - Kenya 1
KW - Kuwait 1
LK - Sri Lanka 1
LU - Lussemburgo 1
LV - Lettonia 1
MT - Malta 1
NI - Nicaragua 1
NP - Nepal 1
OM - Oman 1
PA - Panama 1
PE - Perù 1
PS - Palestinian Territory 1
RS - Serbia 1
SI - Slovenia 1
SN - Senegal 1
SV - El Salvador 1
Totale 8.205
Salva come PNG Salva come JPEG
Città #
Dallas 801
Fairfield 475
Singapore 463
Ashburn 462
Woodbridge 431
Houston 252
Jacksonville 188
San Jose 188
Seattle 178
Chandler 174
Beijing 171
Cambridge 161
Santa Clara 151
Ann Arbor 139
Wilmington 136
Hong Kong 119
New York 96
Los Angeles 72
Munich 70
Nanjing 64
Ho Chi Minh City 63
Izmir 62
San Diego 47
Milan 44
Tokyo 41
Princeton 40
Helsinki 34
Boardman 33
Hanoi 33
Shanghai 33
Lauterbourg 32
London 27
Dong Ket 26
Turku 26
Ferrara 24
Dearborn 22
Bremen 20
Orem 20
São Paulo 20
Addison 16
Hebei 16
Mcallen 16
Mexico City 16
Shenyang 16
Buffalo 15
Brooklyn 14
Nanchang 14
Warsaw 14
Hefei 13
Auburn Hills 12
Denver 12
Lahore 12
Montréal 12
Brussels 11
Frankfurt am Main 11
Tianjin 11
Amsterdam 10
Atlanta 10
Changsha 10
San Francisco 10
Falkenstein 9
Haiphong 9
Manchester 9
Norwalk 9
Philadelphia 9
Stockholm 9
Toronto 9
Baghdad 8
Boston 8
Chennai 8
Da Nang 8
Johannesburg 8
Montreal 8
Phoenix 8
Chicago 7
Council Bluffs 7
Jiaxing 7
Jinan 7
Moscow 7
New Delhi 7
Ningbo 7
Padova 7
Rio de Janeiro 7
Rome 7
Tashkent 7
Bexley 6
Biên Hòa 6
Charlotte 6
Guangzhou 6
Mountain View 6
Dhaka 5
Falls Church 5
Indiana 5
Poplar 5
Tappahannock 5
Washington 5
Ankara 4
Bologna 4
Can Tho 4
Dublin 4
Totale 5.981
Salva come PNG Salva come JPEG
Nome #
1,4-Dioxolane-triazaspirodecanone derivatives as nociceptin/orphanin FQ receptor ligands 995
Chimeric G proteins in fluorimetric calcium assays: Experience with opioid receptors 331
[Dmt(1) ]N/OFQ(1-13)-NH(2) , a potent nociceptin/orphanin FQ and opioid receptor universal agonist. 269
A new ligand for the urotensin II receptor 254
[(t)Bu-d-Gly(5)]NPS, a pure and potent antagonist of the neuropeptide S receptor: In vitro and in vivo studies 251
Structure-activity studies on the nociceptin/orphanin FQ receptor antagonist 1-benzyl-N-{3-[spiroisobenzofuran-1(3H),4′-piperidin-1-yl]propyl} pyrrolidine-2-carboxamide 239
Conformation-activity relationship of neuropeptide S and some structural mutants: Helicity affects their interaction with the receptor 223
Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity 222
Pharmacological characterization of the nociceptin/orphanin FQ receptor non peptide antagonist Compound 24 215
In vitro and in vivo pharmacological characterization of the novel NK(1) receptor selective antagonist Netupitant. 213
Synthesis and biological activity of human neuropeptide S analogues modified in position 2 212
Pharmacological characterisation of novel kinin B2 receptor ligands 210
Further studies at neuropeptide S position 5: Discovery of novel neuropeptide S receptor antagonists 207
Effects of human urotensin II in isolated vessels of various species; comparison with other vasoactive agents 206
null 205
[Arg(14), Lys(15)]nociceptin, a highly potent agonist of the nociceptin/orphanin FQ receptor: in vitro and in vivo studies 204
Synthesis and Biological Activity of Human Neuropeptide S Analogues Modified in Position 5: Identification of Potent and Pure Neuropeptide S Receptor Antagonists 199
Urotensin II stimulates plasma extravasation in mice via UT receptor activation 199
In vitro and in vivo pharmacological characterization of the neuropeptide S receptor antagonist [D-Cys(tBu)5]neuropeptide S 198
Inhibitory effects of putative peptidic urotensin-II receptor antagonists on urotensin-II-induced contraction of cat isolated respiratory smooth muscle 196
Structure-activity study at positions 3 and 4 of human neuropeptide S. 195
Synthesis and separation of the enantiomers of the neuropeptide S receptor antagonist (9R/S)-3-oxo-1,1-diphenyl-tetrahydro-oxazolo[3,4-a]pyrazine-7-carboxylic acid 4-fluoro-benzylamide (SHA 68). 190
Differential agonistic and antagonistic effects of the urotensin-II ligand SB-710411 at rodent and primate UT receptors 187
Pharmacological profile of NOP receptors coupled with calcium signaling via the chimeric protein Gαqi5 183
Comparative biochemical and pharmacological characterization of a novel, NOP receptor selective hexapeptide, Ac-RYYRIR-ol 182
Structure-activity relationship study of position 4 in the urotensin-II receptor ligand U-II(4-11) 179
In vitro and in vivo pharmacological characterization of the novel neuropeptide S receptor ligands QA1 and PI1 178
Structure-activity relationship study on human urotensin II 176
In vitro and in vivo pharmacological characterization of the novel UT receptor ligand [Pen(5), DTrp(7), Dab(8)] urotensin II(4-11) (UFP-803) 172
Pharmacological profile of hemokinin 1: a novel member of the tachykinin family 170
Urantide mimics urotensin-II induced calcium release in cells expressing recombinant UT receptors 168
Structure-activity relationship study on Tyr9 of urotensin-II(4-11): Identification of a partial agonist of the UT receptor 166
The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems 152
Synthesis and Structure-Activity Relationships of (-)-cis-N-Normetazocine-Based LP1 Derivatives 147
Pharmacological profile and antiparkinsonian properties of the novel nociceptin/orphanin FQ receptor antagonist 1-[1-Cyclooctylmethyl-5-(1-hydroxy-1-methyl-ethyl)-1,2,3,6-tetrahydro-pyridin-4-yl]-3-ethyl-1,3-dihydro-benzoimidazol-2-one (GF-4). 111
Further studies on the pharmacological profile of the neuropeptide S receptor antagonist SHA 68. 109
null 94
null 87
null 78
Synthesis and Structure–Activity Relationships of Triazaspirodecanone Derivatives as Nociceptin/Orphanin FQ Receptor Ligands 68
Totale 8.240
Salva come PNG Salva come JPEG
Categoria #
all - tutte 32.297
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 944
Totale 33.241
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202154 0 0 0 0 0 0 0 0 0 0 0 54
2021/2022456 17 52 54 5 31 14 31 26 13 41 41 131
2022/2023439 43 26 15 51 79 59 34 35 56 1 21 19
2023/2024266 21 32 15 8 8 59 11 21 3 4 16 68
2024/2025922 35 27 105 23 108 92 23 36 123 74 137 139
2025/20263.247 292 274 782 322 397 190 289 116 199 259 110 17
Totale 8.240